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Classical and novel protein kinase C (PKC) isozymes
contain two, so-called cysteine-rich zinc finger domains
that represent the binding sites for phorbol esters and
the diacylglycerols. X-ray crystallographic, mutational,
and modeling studies are providing detailed under-
standing of the interactions between the phorbol esters
and individual PKC zinc fingers. In the present study,
we explore the roles of the individual zinc fingers in the
context of the intact enzyme. Our approach was to mu-
tate either the first, the second, or both zinc fingers of
PKCd, to express the mutated enzyme in NIH 3T3 cells,
and to monitor the effect of the mutations on the dose-
response curve for translocation induced by phorbol
12-myristate 13-acetate. The introduced mutations
change into glycine the consensus proline in the phorbol
ester binding loop of the zinc finger; in the isolated zinc
finger, this mutation causes a 125-fold decrease in phor-
bol ester binding affinity. We observed that mutation in
the first zinc finger caused almost no shift in the dose-
response curve for translocation; mutation in the sec-
ond zinc finger caused a 21-fold shift, whereas mutation
in both zinc fingers caused a 138-fold shift. We conclude
that the zinc fingers in the intact PKC are not equiva-
lent and that the second zinc finger plays the predomi-
nant role in translocation of protein kinase Cd in re-
sponse to phorbol 12-myristate 13-acetate. Our findings
have important implications for the understanding and
design of PKC inhibitors targeted to the zinc finger
domains.
Protein kinase C (PKC)1 comprises a family of isozymes that
mediate signal transduction for the lipophilic second messen-
ger diacylglycerol, regulating a wide array of cellular processes
(see Refs. 1 and 2 for review). PKC possesses two functional
domains, an N-terminal regulatory domain and a C-terminal
catalytic domain. Within the regulatory domain lie two cys-
teine-rich zinc fingers, responsible for recognition by PKC of
diacylglycerol or their ultrapotent analogs, the phorbol esters.
In isolation, the individual first and second zinc fingers bind
phorbol ester with similar affinities (3, 4), and the molecular
details of the interaction between the phorbol esters and the
zinc finger domain are beginning to emerge. NMR spectroscopy
has yielded the solution structure of the second zinc finger of
PKCa (5, 6); the structure of the complex between the second
zinc finger of PKCd and phorbol 13-acetate has been solved by
x-ray crystallography (7). Site-directed mutagenesis has fur-
ther highlighted key residues within the zinc finger structure
required for ligand binding (8), and computer modeling is pro-
viding insight into how other high affinity ligands, e.g. the
indole alkaloids, interact with the zinc finger.
An issue that is only beginning to be addressed is the role of
the individual zinc fingers within the context of the intact PKC
molecule. In pioneering studies, Bell and co-workers (9) had
reported that the binding affinity of the second zinc finger of
PKCg was reduced in constructs containing sequences C-ter-
minal to the zinc finger. Riedel and co-workers (10) analyzed
the effect of the deletion of the first or second zinc finger of
PKCa in a phenotypic yeast assay; they reported that PMA
showed a comparable loss in potency for activation of the dele-
tion mutants at either site; mezerein activated predominantly
through the first zinc finger, whereas (2)-indolactam V re-
quired both intact zinc fingers for activity. Unfortunately, in-
terpretation of the results of deletion analysis is clouded by the
extent of potential disruption of the structure of the holoen-
zyme; for example, the deletion of the first zinc finger also
included the pseudosubstrate domain immediately N-terminal
to it.
As an alternative approach, we have introduced a proline to
glycine mutation into the first or second or both zinc fingers of
PKCd. We had previously reported that this mutation, in the
isolated zinc finger, preserves binding activity but causes a
substantial loss (125-fold) in binding affinity (8). We evaluated
the quantitative influence of these mutations on recognition of
phorbol 12-myristate 13-acetate in the intact cell, using as an
end point translocation of the mutant PKC from the soluble to
the detergent-soluble particulate fraction. We report here that
the zinc fingers in the intact PKC are not equivalent for induc-
ing translocation and that the second zinc finger in the intact
PKC has approximately 25-fold higher affinity for PMA than
does the first zinc finger under these cellular conditions.
EXPERIMENTAL PROCEDURES
Phorbol 12-myristate 13-acetate was purchased from LC Laborato-
ries (Woburn, MA) and dissolved in ethanol.
For site-directed mutagenesis of PKCd, mouse PKCd (a kind gift of H.
Mischak and F. J. Mushinski) was cloned into the pGEM-T vector
(Promega, Madison, WI) as described previously (11). This plasmid
served as our “master” vector for site-directed mutagenesis using the
same selection primer as described in Ref. 11. The following oligonu-
cleotides served as mutagenesis primers. 1) 59-ACCTTCTTC-
GGGCAGGGTACCTTCTGTTCT-39 mutates the proline residue at po-
sition 169 into a glycine (bold letters) and creates the underlined KpnI
restriction site to facilitate the detection of mutant plasmids. 2) 59-
AACTACATGAGCGGTACCTTCTGTGACCAC-39 mutates the proline
residue at position 241 into a glycine (bold letters) and creates the
underlined KpnI restriction site to facilitate the detection of mutant
plasmids. The mutations were confirmed by direct sequencing (Paragon
Biotech Inc., Baltimore, MD). The single mutants proline to glycine at
site 169 (P169G), proline to glycine at site 241 (P241G), and the double
mutant (P169G/P241G) were subcloned, along with the wild type, into
an epitope tagging mammalian expression vector described elsewhere
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(12). The constructs were transfected into NIH 3T3 fibroblasts using
Lipofectamine (Life Technologies, Inc.) and selected as described else-
where (11).
For the assessment of the amounts of soluble and membrane-associ-
ated mutant and wild type PKCd, the cells were routinely treated with
the indicated doses of PMA for 10 min, 30 min, 1 h, and 6 h at 37 °C. The
cells were harvested and lysed, and the soluble and Triton X-100-
soluble particulate fractions were prepared as described previously. The
protein samples were subjected to SDS-PAGE and transferred to nitro-
cellulose membranes. The protein content of individual samples was
determined (13), and the blots were stained using the polyclonal anti-
PKCe antibody from Life Technologies, Inc. as described previously
(13). The densitometric analysis of the immunoblots and the normal-
ization to the protein content of each individual lane were performed as
described (13).
RESULTS AND DISCUSSION
Using a previously described tagging system (12) we could
readily distinguish the endogenous and overexpressed PKCd.
The tagged, overexpressed wild type PKCd translocated with a
time course and dose-response curve similar to that of the
endogenous enzyme (data not shown), arguing against artifacts
caused by the overexpression (13). Previously we had shown
that the kinetics of translocation in response to various PKC
activators depended on the PKC isozyme and the cellular sys-
tem (14). Under the present conditions, the translocation dose-
response curves for the mutant and wild type PKC d were
stable by 60 min of exposure to PMA, and at this time point
down-regulation was not yet detectable (data not shown and
Ref. 13). We therefore determined the dose-response curves for
translocation at this time point (Fig. 1). Data were fitted to the
Hill equation.
PMA translocated the wild type form of PKCd with an ED50
of 13 6 1 nM, showing excellent correlation with the data
obtained for the endogenous enzyme in a previous publication
(13). Mutation in the first zinc finger (P169G) caused a barely
detectable 1.1-fold shift. Mutation in the second zinc finger
alone (P241G) caused an approximately 21-fold shift, whereas
mutations in both zinc fingers caused an approximately 138-
fold shift (Fig. 2, Table I). Qualitatively, these data demon-
strate that the two zinc fingers are not equivalent and the
second zinc finger is the primary contributor to translocation of
the native enzyme.
Quantitatively, the observed behavior is consistent with the
following model. We assumed that PKC exists in four possible
states in the presence of phorbol esters: 1) when no phorbol
ester is bound to any of the zinc fingers (P0); 2) when only the
first zinc finger binds phorbol ester (P1); 3) when only the
second zinc finger binds phorbol ester (P2); and 4) when both
zinc fingers bind phorbol ester (P1,2). Under equilibrium con-
ditions the following equations describe the amount of PKC in
the individual states,
[L] [P0] 5 k1 [P1] (Eq. 1)
[L] [P0] 5 k2 [P2] (Eq. 2)
[L] [P1] 5 k3 [P1,2] (Eq. 3)
[L] [P2] 5 k4 [P1,2] (Eq. 4)
where [L] is the concentration of the free phorbol ester, and k1
through k4 are the apparent dissociation constants for the
individual equilibria.
Assuming that binding of phorbol ester to any or both zinc
fingers causes translocation, the ratio of translocated to total
PKC is described by the following equation.
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FIG. 1. Dose-dependent translocation of the wild type and mu-
tant forms of PKCd by PMA. NIH 3T3 fibroblasts transfected with
the wild type or mutant forms of PKCd were treated by the indicated
doses of PMA for 60 min. The soluble fraction was prepared for SDS-
PAGE, and Western immunoblotting was performed as described under
“Experimental Procedures.” Equal amounts of protein of the cytosolic
fraction (10 mg of protein/lane) were loaded in each lane. Identical
results were obtained in three independent sets of experiments.
FIG. 2. PMA-induced changes in levels of wild type andmutant
PKCd in the cytosolic fraction of NIH 3T3 fibroblasts. NIH 3T3
fibroblasts transfected with the wild type or mutant forms of PKCd
were treated by the indicated doses of PMA for 60 min. The soluble
fraction was prepared for SDS-PAGE, and Western immunoblotting
was performed as described under “Experimental Procedures.” The
amount of the enzyme was quantitated by densitometry and expressed
as the percentage of the amount of isozyme present in the soluble
fraction in the control. The illustrated curves are calculated from the
Hill equation. Points represent the average of four independent exper-
iments 6 S.E.
TABLE I
Potency of PMA to induce translocation of the wild type and
mutant forms of PKCd
ED50 and Hill coefficient values were determined from fitting of the
data to the Hill equation or the kinetic model (Equation 5). The ED50
and Hill coefficient values 6 S.E. were derived from four independent
experiments.
Fit to Hill equation Fit to kinetic model
ED50
Hill
coefficient ED50
Hill
coefficient
nM nM
PKCd wild type 15 6 0.6 0.9 6 0.03 13.6 1.10
PKCd P169G 16 6 0.5 0.7 6 0.02 15 1.00
PKCd P241G 270 6 10 1.35 6 0.04 250 1.22
PKCd P169G/P241G 1900 6 70 1.0 6 0.03 1660 1.10
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The concentration of phorbol ester at which half of the PKC
is translocated, that is the ED50 value of the translocation
dose-response curve, is as follows.
[L0.5] 5
2 ~@k3# 1 @k4#! 1 Î~@k3# 1 @k4#!2 1 4@k1#@k3#
2
(Eq. 6)
Solving Equation 5, fitting it to the dose-response data for
translocation (Fig. 2), we obtained the following apparent dis-
sociation constants: 390 nM for k1, 15 nM for k2, 8.9 nM for k3,
and 230 nM for k4, assuming that the dissociation constant of
phorbol ester to each zinc finger is changed by a factor of 125 (7)
upon the proline-glycine mutation. The shapes and slopes of
the translocation curves as well as the ED50 values predicted
from these parameters and Equation 5 show good agreement
with the experimental data (Fig. 2) and with the empirical fit to
the Hill equation (Table I).
The derived parameters for translocation assist in the con-
ceptual understanding of aspects of our experimental findings.
Because of the difference between the zinc fingers in binding
affinities, the first zinc finger has little influence on the ED50
for translocation either in the wild type or double mutant
(contributing only 3.4% to the total translocation at the ED50)
and negligible influence in the first zinc finger mutant (only
0.03% contribution to the total). This lack of contribution of the
first zinc finger explains two otherwise paradoxical features.
First, why the double mutant shows only a 138-fold shift in
dose-response curve rather than a shift of 125 3 125-fold (i.e.
15,625-fold), which would have been expected had both zinc
fingers contributed equally. Second, why the translocation fails
to show strong positive cooperativity with a Hill coefficient
significantly larger than 1. Consistent with our model, the one
mutant showing cooperativity is that in the second zinc finger,
for which the two affinities are closest to one another and an
effect on binding to both zinc fingers can be manifest.
Our ongoing analysis, requiring different molecular con-
structs and methodologies, will hopefully provide insight into
the relationship of the zinc fingers in translocation vis-a-vis
other measures of PKC-ligand interaction such as enzymatic
activation or ligand binding as determined directly.
The findings reported here that the second zinc finger of
PKCd suffices for PKC translocation by PMA should not be
overgeneralized. The model of PKC activation that emerged
from the x-ray crystallographic structure for the zinc finger-
phorbol ester complex (7) was that the phorbol ester capped a
hydrophilic cleft in an otherwise hydrophobic surface on the
zinc finger, promoting its ability to interact with the mem-
brane. Obviously, two features of the phorbol ester will contrib-
ute to the energy of the ternary phorbol ester-zinc finger-
phospholipid complex: 1) the ability of the functional groups of
the phorbol ester to form hydrogen bonds with the correspond-
ing functional groups within the cleft, together with van der
Waals interactions between hydrophobic residues of the phor-
bol ester and corresponding hydrophobic regions in the cleft; 2)
hydrophobic interactions of the phorbol ester side chains with
the membrane. This latter contribution is what makes PMA a
more potent ligand than phorbol 12,13-diacetate (15), for ex-
ample. Whether the combination of these contributions to sta-
bilization of the ternary complex is sufficient to drive mem-
brane translocation upon occupancy of the second zinc finger
alone will necessarily depend on the nature and concentration
of the ligand, on the degree of negative surface charge of the
membrane, and on other factors that may stabilize the un-
folded form of the enzyme, i.e. occupancy of the catalytic site.
Consistent with this concept, Riedel reported that the rela-
tively hydrophilic ligand (2)-indolactam V was only able to
generate a PKC response in yeast when neither zinc finger had
been deleted (10).
Our demonstration that the two zinc fingers of PKCd are not
equivalent for PKC translocation in NIH 3T3 cells agrees with
the lack of equivalence reported by Riedel and co-workers using
constructs of PKCa deleted in the individual zinc fingers and
analyzed for their ability to modulate yeast cell growth as a
function of ligand concentration (10). It likewise agrees quali-
tatively with the elegant study from Stubbs and co-workers
(16) demonstrating biphasic binding in vitro to PKCa using the
fluorescent phorbol ester analog sapintoxin D. In both cases,
however, the substantial difference in methodologies prevents
detailed comparison. Our current findings provide a framework
for interpreting our earlier report, using PKCa, that we could
distinguish two different interactions of phorbol esters with
PKC that differed both in affinity and structure-activity (15).
Under conditions limiting for membrane association, PKCa
enzymatic activation required higher phorbol ester concentra-
tions than did binding and had a greater dependence on the
lipophilicity of the ligand. Although the full consequences of the
asymmetry in the zinc fingers of PKC remain to be resolved,
this issue appears to have great potential for the development
of ligands that have novel effects on the PKC pathway.
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